imazodan has been researched along with Heart Failure in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobowski, G; Bristol, JA; Burke, SE; Evans, DB; Newton, RS; Sircar, I; Steffen, RP; Weishaar, RE | 1 |
| Bobowski, G; Bristol, JA; Duell, BL; Evans, DB; Sircar, I | 1 |
| Erhardt, PW | 1 |
| Bristol, JA; Evans, DB; Moos, WH; Sircar, I; Weishaar, RE | 1 |
| Goldberg, AD; Goldstein, S; Nicklas, J | 1 |
| Burlew, BS; Goldberg, AD; Goldstein, S; Jafri, SM; Rogers, A | 1 |
| Bing, RJ; Hartmann, A; Saeed, M; Sütsch, G | 1 |
| Bourdillon, PD; Cheng, D; Latts, J; Nicklas, J; Olsen, S; Pitt, B; Terris, S | 1 |
2 review(s) available for imazodan and Heart Failure
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Failure; Humans; Myocardial Contraction; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1987 |
[Phosphodiesterase inhibition as a new positive-inotropic principle].
Topics: 2,2'-Dipyridyl; Animals; Benzimidazoles; Cardiotonic Agents; Heart Failure; Humans; Imidazoles; Myocardial Contraction; Phosphodiesterase Inhibitors; Phthalazines; Pyridazines; Stimulation, Chemical | 1986 |
2 trial(s) available for imazodan and Heart Failure
| Article | Year |
|---|---|
Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group.
Topics: Administration, Oral; Cardiac Complexes, Premature; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Tolerance; Electrocardiography, Ambulatory; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Placebos; Pyridazines; Safety; Stroke Volume; Time Factors | 1991 |
Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Phosphodiesterase Inhibitors; Pulmonary Wedge Pressure; Pyridazines; Time Factors; Vascular Resistance | 1986 |
4 other study(ies) available for imazodan and Heart Failure
| Article | Year |
|---|---|
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiotonic Agents; Dogs; Female; Fibrinolytic Agents; Heart Failure; Humans; Imidazoles; Male; Myocardial Contraction; Platelet Aggregation; Pyridazines; Structure-Activity Relationship; Vasodilator Agents | 1989 |
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Chemical Phenomena; Chemistry, Physical; Dogs; Heart Failure; Imidazoles; Myocardial Contraction; Pyridazines; Structure-Activity Relationship | 1985 |
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dogs; Guinea Pigs; Heart Failure; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridazines | 1984 |
Effects of CI-914 in congestive heart failure due to coronary artery disease or idiopathic cardiomyopathy.
Topics: Adult; Aged; Cardiac Output; Cardiotonic Agents; Coronary Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pulmonary Wedge Pressure; Pyridazines; Vascular Resistance | 1986 |